PROCEPT BioRobotics 配当と自社株買い

配当金基準チェック /06

PROCEPT BioRobotics配当金を支払った記録がありません。

主要情報

n/a

配当利回り

-0.3%

バイバック利回り

総株主利回り	-0.3%
将来の配当利回り	0%
配当成長	n/a
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	n/a
配当性向	n/a

最近の配当と自社株買いの更新

更新なし

Recent updates

Earnings Update: Here's Why Analysts Just Lifted Their PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Price Target To US$102

Oct 31

Procept BioRobotics: New Hydros Aquablation System To Fuel Next Leg Of Growth

Sep 12

Procept BioRobotics: Risk Capital Unlock With FDA Hydros Approval

Aug 27

Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects As Shares Rocket 28%

Aug 25

Here's What Analysts Are Forecasting For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) After Its Second-Quarter Results

Aug 04

PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce

May 21

The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

Apr 05

US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Mar 01

Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt

Feb 07

Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher

Dec 14

Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?

Feb 27

Need To Know: Analysts Are Much More Bullish On PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Revenues

May 10

決済の安定と成長

配当データの取得

安定した配当: PRCTの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: PRCTの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

PROCEPT BioRobotics 配当利回り対市場

PRCT 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (PRCT)	n/a
市場下位25% (US)	1.4%
市場トップ25% (US)	4.3%
業界平均 (Medical Equipment)	1.6%
アナリスト予想 (PRCT) (最長3年)	0%

注目すべき配当: PRCTは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: PRCTは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: PRCTの配当性向を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: PRCTが配当金を報告していないため、配当金の持続可能性を計算できません。

PROCEPT BioRobotics 配当と自社株買い

配当金 基準チェック /06

主要情報

最近の配当と自社株買いの更新

Recent updates

Earnings Update: Here's Why Analysts Just Lifted Their PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Price Target To US$102

PROCEPT BioRobotics Corporation has completed a Follow-on Equity Offering in the amount of $174.999916 million.

PROCEPT BioRobotics Corporation has completed a Follow-on Equity Offering in the amount of $175 million.

PROCEPT BioRobotics Corporation has filed a Follow-on Equity Offering in the amount of $175 million.

PROCEPT BioRobotics Corporation to Report Q3, 2024 Results on Oct 28, 2024

PROCEPT BioRobotics Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate Cancer

Procept BioRobotics: New Hydros Aquablation System To Fuel Next Leg Of Growth

Procept BioRobotics: Risk Capital Unlock With FDA Hydros Approval

Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects As Shares Rocket 28%

PROCEPT BioRobotics Announces FDA Clearance of the HYDROS™ Robotic System, the Next-Generation, AI-Powered Platform for Aquablation® Therapy

Here's What Analysts Are Forecasting For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) After Its Second-Quarter Results

PROCEPT BioRobotics Corporation Revises Revenue Guidance for Full Year 2024

PROCEPT BioRobotics Corporation to Report Q2, 2024 Results on Aug 01, 2024

PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce

PROCEPT BioRobotics Corporation Announces Long-Term, Real-World Data Showing the Benefits of Aquablation Therapy for the Treatment of Symptomatic Prostatic Hyperplasia

Independent Director notifies of intention to sell stock

Price target increased by 13% to US$65.00

Procept Biorobotics Corporation Increases Revenue Guidance for Full Year 2024

First quarter 2024 earnings released: US$0.51 loss per share (vs US$0.63 loss in 1Q 2023)

PROCEPT BioRobotics Corporation, Annual General Meeting, Jun 04, 2024

The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

PROCEPT BioRobotics Corporation to Report Q1, 2024 Results on May 01, 2024

President recently sold US$263k worth of stock

Executive VP & CFO exercised options to buy US$2.6m worth of stock.

President recently sold US$428k worth of stock

Independent Director notifies of intention to sell stock

US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Price target increased by 11% to US$56.67

PROCEPT BioRobotics Corporation Provides Revenue Guidance for the Full Year 2024

Full year 2023 earnings: EPS misses analyst expectations

Executive VP & CFO notifies of intention to sell stock

Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt

Price target increased by 7.3% to US$51.17

Price target increased by 12% to US$50.33

Executive VP & CFO exercised options and sold US$702k worth of stock

PROCEPT BioRobotics Corporation to Report Q4, 2023 Results on Feb 27, 2024

Price target increased by 7.6% to US$47.17

Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher

Independent Chairman of the Board recently sold US$3.1m worth of stock

Executive VP & CFO notifies of intention to sell stock

Price target decreased by 7.9% to US$40.67

Independent Director recently sold US$805k worth of stock

Independent Director notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

PROCEPT BioRobotics Corporation Revises Revenue Guidance for the Full Year 2023

PROCEPT BioRobotics Corporation to Report Q3, 2023 Results on Nov 01, 2023

Procept Biorobotics Corporation Receives U.S. Fda Investigational Device Exemption to Investigate Aquablation Therapy for Prostate Cancer

PROCEPT Biorobotics Corporation Announces First Commercial Aquablation Therapy Procedures in Japan

Price target decreased by 7.6% to US$47.29

PROCEPT BioRobotics Corporation has completed a Follow-on Equity Offering in the amount of $149.999972 million.

Insider exercised options and sold US$280k worth of stock

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

PROCEPT BioRobotics Corporation Revises Earnings Guidance for the Year 2023

PROCEPT BioRobotics Corporation to Report Q2, 2023 Results on Jul 27, 2023

Executive VP & CFO recently sold US$795k worth of stock

Insider exercised options to buy US$366k worth of stock.

First quarter 2023 earnings: EPS misses analyst expectations

President recently sold US$170k worth of stock

Executive VP & CFO recently sold US$1.0m worth of stock

Independent Director notifies of intention to sell stock

No longer forecast to breakeven

Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?

PROCEPT BioRobotics Corporation to Report Q4, 2022 Results on Feb 28, 2023

Now 22% undervalued

High number of new directors

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

PROCEPT BioRobotics Corporation Projects Earnings Guidance for the Full Year 2022

Now 20% undervalued

PROCEPT BioRobotics Corporation to Report Q3, 2022 Results on Nov 03, 2022

Procept Biorobotics announces $52M debt refinancing

Providence announces national contract for PROCEPT Biorobotics Aquabeam Systems

Procept BioRobotics Has Resources To Ramp Up Commercialization

PROCEPT BioRobotics Corporation Revises Earnings Guidance for the Year 2022

Second quarter 2022 earnings released: US$0.43 loss per share (vs US$2.61 loss in 2Q 2021)

配当金基準チェック /06